Skip to main content
SpringerLink
Log in

Neuromuscular Junction Disorders

  • Chapter
  • First Online:
Neurorheumatology

  • 984 Accesses

Abstract

This chapter reviews the latest developments in the epidemiology, pathophysiology, diagnosis, and treatment of autoimmune myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS). The biologic and phenotypic heterogeneity of MG is highlighted, and the effect of this heterogeneity on disease course, choice of treatment, and response to therapy is emphasized. Discussion of myasthenia subtypes and additional references for further reading are provided. The approach to diagnosis and management of paraneoplastic and autoimmune LEMS is also reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gilhus NE. Myasthenia gravis. N Engl J Med. 2016;375(26):2570–81.

    Article  CAS  PubMed  Google Scholar 

  2. Guptill JT, Soni M, Meriggioli MN. Current treatment, emerging translational therapies, and new therapeutic targets for autoimmune myasthenia gravis. Neurotherapeutics. 2015;13(1):118–31.

    Article  PubMed Central  CAS  Google Scholar 

  3. Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S. Myasthenia gravis — autoantibody characteristics and their implications for therapy. Nat Rev Neurol. 2016;12(5):259–68.

    Article  CAS  PubMed  Google Scholar 

  4. Cavalcante P, Bernasconi P, Mantegazza R. Autoimmune mechanisms in myasthenia gravis. Curr Opin Neurol. 2012;25(5):621–9.

    Article  CAS  PubMed  Google Scholar 

  5. Pirskanen R. Genetic aspects in myasthenia gravis. Acta Neurol Scand. 1977;56(5):365–88.

    Article  CAS  PubMed  Google Scholar 

  6. Renton AE, Pliner HA, Provenzano C, Evoli A, Ricciardi R, Nalls MA, et al. A genome-wide association study of myasthenia gravis. JAMA Neurol. 2015;72(4):396–404.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Sanders D, Massey JM. Clinical features of myasthenia gravis. In: Engel AG, editor. Handbook of clinical neurology: neuromuscular junction disorders. Edinburgh/New York: Elsevier; 2008. p. 229–53.

    Chapter  Google Scholar 

  8. Benatar M, Mcdermott MP, Sanders DB, Wolfe GI, Barohn RJ, Nowak RJ, et al. Muscle study group (MSG). Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial. Muscle Nerve. 2016;53(3):363–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus guidance for management of myasthenia gravis. Neurology. 2016;87(4):419–25.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Muppidi S. Outcome measures in myasthenia gravis: incorporation into clinical practice. J Clin Neuromuscul Dis. 2017;18(3):135–46.

    Article  PubMed  Google Scholar 

  11. Juel VC, Massey JM. Myasthenia gravis. Orphanet J Rare Dis. 2007;2(1):44.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37(2):141–9.

    Article  PubMed  Google Scholar 

  13. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5):475–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Sanders DB, Guptill JT. Myasthenia gravis and Lambert-Eaton myasthenic syndrome. Continuum (Minneap Minn). 2014;20(5 Peripheral Nervous System Disorders):1413–25.

    Google Scholar 

  15. Decroos EC, Hobson-Webb LD, Juel VC, Massey JM, Sanders DB. Do acetylcholine receptor and striated muscle antibodies predict the presence of thymoma in patients with myasthenia gravis? Muscle Nerve. 2013;49(1):30–4.

    Article  CAS  Google Scholar 

  16. Rodríguez Cruz PM, Al-Hajjar M, Huda S, Jacobson L, Woodhall M, Jayawant S, et al. Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis. JAMA Neurol. 2015;72(6):642–9.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Juel VC. Evaluation of neuromuscular junction disorders in the electromyography laboratory. Neurol Clin. 2012;30(2):621–39.

    Article  PubMed  Google Scholar 

  18. Pascuzzi RM. The edrophonium test. Semin Neurol. 2003;23(1):83–8.

    Article  PubMed  Google Scholar 

  19. Sethi KD, Rivner MH, Swift TR. Ice pack test for myasthenia gravis. Neurology. 1987;37:1383–5.

    Article  CAS  PubMed  Google Scholar 

  20. Priola AM, Priola SM. Imaging of thymus in myasthenia gravis: from thymic hyperplasia to thymic tumor. Clin Radiol. 2014;69(5):e230–45.

    Article  CAS  PubMed  Google Scholar 

  21. Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol. 1984;15(3):291–8.

    Article  CAS  PubMed  Google Scholar 

  22. Howard JF, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Eculizumab Study Group, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976–86.

    Article  CAS  PubMed  Google Scholar 

  23. Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, et al., MGTX Study Group. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med 2016;375(6):511–22.

    Google Scholar 

  24. Evoli A, Minisci C, Di Schino C, Marsili F, Punzi C. Thymoma in patients with MG characteristics and long-term outcome. Neurology. 2002;59:1844–50.

    Article  CAS  PubMed  Google Scholar 

  25. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7(3):365–8.

    Article  CAS  PubMed  Google Scholar 

  26. Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011;44(1):36–40.

    Article  PubMed  Google Scholar 

  27. Hehir MK, Hobson-Webb LD, Benatar M, Barnett C, Silvestri NJ, Howard JF Jr, et al. Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review. Neurology. 2017;89(10):1069–77.

    Article  CAS  PubMed  Google Scholar 

  28. Zisimopoulou P, Evangelakou P, Tzartos J, Lazaridis K, Zouvelou V, Mantegazza R, et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun. 2014;52:139–45.

    Article  CAS  PubMed  Google Scholar 

  29. Makarious D, Horwood K, Coward JIG. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017;82:128–36.

    Article  CAS  PubMed  Google Scholar 

  30. Wendell LC, Levine JM. Myasthenic crisis. The Neurohospitalist. 2011;1(1):16–22.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Leite MI, Coutinho E, Lana-Peixoto M, Apostolos S. Myasthenia gravis and neuromyelitis optica spectrum disorder a multicenter study of 16 patients. Neurology. 2012;78:1601–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Massey JM, De Jesus-Acosta C. Pregnancy and myasthenia gravis. Continuum (Minneap Minn). 2014;20(1 Neurology of Pregnancy):115–27.

    Google Scholar 

  33. Sanders DB, Juel VC, Harati Y, Smith AG, Peltier AC, Marburger T, Lou J-S, Pascuzzi RM, Richman DP, Xie T, Demmel V, Jacobus LR, Aleš KL, Jacobus DP. 3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia. Muscle Nerve. 2017;57(4):561–8.

    Article  CAS  Google Scholar 

  34. Oh SJ, Shcherbakova N, Kostera-Pruszczyk A, Alsharabati M, Dimachkie M, Blanco JM, Brannagan T, Lavrnić D, Shieh PB, Vial C, Meisel A, Komoly S, Schoser B, Sivakumar K, So Y. Amifampridine phosphate (Firdapse ) is effective and safe in a phase 3 clinical trial in LEMS. Muscle Nerve. 2016;53(5):717–25.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Harvard Medical School, Boston, MA, USA

    Amanda C. Guidon

  2. Department of Neurology, Massachusetts General Hospital, Boston, MA, USA

    Amanda C. Guidon

  3. Division of Neuromuscular Medicine, Neuromuscular Diagnostic Center, Boston, MA, USA

    Amanda C. Guidon

Authors
  1. Amanda C. Guidon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amanda C. Guidon .

Editor information

Editors and Affiliations

  1. Division of Neuroimmunology, University of Iowa, Iowa City, IA, USA

    Tracey A. Cho

  2. Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Shamik Bhattacharyya

  3. Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Simon Helfgott

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Guidon, A.C. (2019). Neuromuscular Junction Disorders. In: Cho, T., Bhattacharyya, S., Helfgott, S. (eds) Neurorheumatology. Springer, Cham. https://doi.org/10.1007/978-3-030-16928-2_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-16928-2_23

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-16927-5

  • Online ISBN: 978-3-030-16928-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation